Minerva Neurosciences, Inc. (NERV) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
17/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseNERV / S&P -7.88% / 15.20% |
LoseNERV / S&P NERV unavailable / 15.00% |
LoseNERV / S&P -2582.43% / 50.40% |
| 2026-Q11/3 |
WinNERV / S&P 49.88% / -4.33% |
LoseNERV / S&P NERV unavailable / 11.30% |
LoseNERV / S&P -4615.85% / 27.70% |
| 2025-Q41/3 |
WinNERV / S&P 90.97% / 2.65% |
LoseNERV / S&P NERV unavailable / 9.00% |
LoseNERV / S&P -18347.37% / 13.40% |
| 2025-Q32/3 |
WinNERV / S&P 22.38% / 8.12% |
LoseNERV / S&P NERV unavailable / 4.61% |
WinNERV / S&P 311.11% / 13.45% |
| 2025-Q20/3 |
LoseNERV / S&P 1.18% / 10.94% |
LoseNERV / S&P NERV unavailable / 4.83% |
LoseNERV / S&P -133.26% / 10.63% |
| 2025-Q10/3 |
LoseNERV / S&P -23.49% / -4.27% |
LoseNERV / S&P NERV unavailable / 4.98% |
LoseNERV / S&P -118.30% / 10.57% |
| 2024-Q40/3 |
LoseNERV / S&P -16.78% / 2.41% |
LoseNERV / S&P NERV unavailable / 5.25% |
LoseNERV / S&P -104.08% / 6.15% |
| 2024-Q30/3 |
LoseNERV / S&P -16.30% / 5.89% |
LoseNERV / S&P NERV unavailable / 5.89% |
LoseNERV / S&P -90.47% / 6.11% |
| 2024-Q21/3 |
WinNERV / S&P 23.64% / 4.28% |
LoseNERV / S&P NERV unavailable / 5.38% |
LoseNERV / S&P -10.64% / 5.12% |
| 2024-Q10/3 |
LoseNERV / S&P -58.05% / 10.56% |
LoseNERV / S&P NERV unavailable / 5.71% |
LoseNERV / S&P -18.40% / 5.59% |
| 2023-Q40/3 |
LoseNERV / S&P -10.87% / 11.69% |
LoseNERV / S&P NERV unavailable / 6.81% |
LoseNERV / S&P -22.46% / 7.78% |
| 2023-Q30/3 |
LoseNERV / S&P -24.51% / -3.27% |
LoseNERV / S&P NERV unavailable / 7.52% |
LoseNERV / S&P -46.00% / -5.03% |
| 2023-Q21/3 |
WinNERV / S&P 471.25% / 8.74% |
LoseNERV / S&P NERV unavailable / 9.50% |
LoseNERV / S&P -45.69% / -8.57% |
| 2023-Q10/3 |
LoseNERV / S&P 0.63% / 7.50% |
LoseNERV / S&P NERV unavailable / 10.77% |
LoseNERV / S&P -29.53% / -15.69% |
| 2022-Q40/3 |
LoseNERV / S&P -82.77% / 7.56% |
LoseNERV / S&P NERV unavailable / 11.88% |
LoseNERV / S&P NERV unavailable / -17.99% |
| 2022-Q31/3 |
WinNERV / S&P 178.85% / -4.88% |
LoseNERV / S&P NERV unavailable / 13.47% |
LoseNERV / S&P NERV unavailable / -1.41% |
| 2022-Q20/3 |
LoseNERV / S&P -50.15% / -16.10% |
LoseNERV / S&P NERV unavailable / 13.71% |
LoseNERV / S&P NERV unavailable / 11.04% |
| 2022-Q11/3 |
WinNERV / S&P 3.62% / -4.60% |
LoseNERV / S&P NERV unavailable / 15.97% |
LoseNERV / S&P NERV unavailable / 42.23% |
| 2021-Q40/3 |
LoseNERV / S&P -53.97% / 11.03% |
LoseNERV / S&P NERV unavailable / 15.00% |
LoseNERV / S&P NERV unavailable / 96.40% |
| 2021-Q30/3 |
LoseNERV / S&P -25.00% / 0.58% |
LoseNERV / S&P NERV unavailable / 10.77% |
LoseNERV / S&P NERV unavailable / 69.42% |
| 2021-Q20/3 |
LoseNERV / S&P -20.55% / 8.55% |
LoseNERV / S&P NERV unavailable / 6.58% |
LoseNERV / S&P NERV unavailable / 51.81% |
| 2021-Q11/3 |
WinNERV / S&P 24.79% / 6.17% |
LoseNERV / S&P NERV unavailable / -1.06% |
LoseNERV / S&P NERV unavailable / 7.39% |
| 2020-Q40/3 |
LoseNERV / S&P -26.42% / 12.15% |
LoseNERV / S&P NERV unavailable / -3.72% |
LoseNERV / S&P NERV unavailable / -33.42% |
| 2020-Q30/3 |
LoseNERV / S&P -11.91% / 8.93% |
LoseNERV / S&P NERV unavailable / -2.04% |
LoseNERV / S&P NERV unavailable / -27.10% |
| 2020-Q20/3 |
LoseNERV / S&P -40.03% / 20.54% |
LoseNERV / S&P NERV unavailable / -0.46% |
LoseNERV / S&P NERV unavailable / -27.11% |
| 2020-Q11/3 |
WinNERV / S&P -15.33% / -19.60% |
LoseNERV / S&P NERV unavailable / 3.47% |
LoseNERV / S&P NERV unavailable / -14.75% |
| 2019-Q40/3 |
LoseNERV / S&P -8.26% / 9.07% |
LoseNERV / S&P NERV unavailable / 5.36% |
LoseNERV / S&P NERV unavailable / 2.99% |
| 2019-Q31/3 |
WinNERV / S&P 37.66% / 1.70% |
LoseNERV / S&P NERV unavailable / 5.02% |
LoseNERV / S&P NERV unavailable / 0.21% |
| 2019-Q20/3 |
LoseNERV / S&P -28.37% / 4.30% |
LoseNERV / S&P NERV unavailable / 6.64% |
LoseNERV / S&P NERV unavailable / 8.65% |
| 2019-Q11/3 |
WinNERV / S&P 16.62% / 13.65% |
LoseNERV / S&P NERV unavailable / 8.12% |
LoseNERV / S&P NERV unavailable / 14.29% |
| 2018-Q40/3 |
LoseNERV / S&P -46.29% / -13.52% |
LoseNERV / S&P NERV unavailable / 9.05% |
LoseNERV / S&P NERV unavailable / 18.23% |
| 2018-Q31/3 |
WinNERV / S&P 52.12% / 7.71% |
LoseNERV / S&P NERV unavailable / 10.21% |
LoseNERV / S&P NERV unavailable / 19.06% |
| 2018-Q21/3 |
WinNERV / S&P 32.00% / 3.43% |
LoseNERV / S&P NERV unavailable / 9.03% |
LoseNERV / S&P NERV unavailable / 14.46% |
| 2018-Q11/3 |
WinNERV / S&P 3.31% / -0.76% |
LoseNERV / S&P NERV unavailable / 7.68% |
LoseNERV / S&P NERV unavailable / 12.46% |
| 2017-Q40/3 |
LoseNERV / S&P -20.39% / 6.64% |
LoseNERV / S&P NERV unavailable / 7.03% |
LoseNERV / S&P NERV unavailable / 13.82% |
| 2017-Q30/3 |
LoseNERV / S&P -14.12% / 4.48% |
LoseNERV / S&P NERV unavailable / 5.68% |
LoseNERV / S&P NERV unavailable / 17.57% |
| 2017-Q21/3 |
WinNERV / S&P 9.26% / 3.09% |
LoseNERV / S&P NERV unavailable / 4.83% |
LoseNERV / S&P NERV unavailable / 17.74% |
| 2017-Q10/3 |
LoseNERV / S&P -31.06% / 6.07% |
LoseNERV / S&P NERV unavailable / 3.67% |
LoseNERV / S&P NERV unavailable / 13.32% |
| 2016-Q40/3 |
LoseNERV / S&P -16.76% / 3.82% |
LoseNERV / S&P NERV unavailable / 2.09% |
LoseNERV / S&P NERV unavailable / 7.05% |
| 2016-Q31/3 |
WinNERV / S&P 38.25% / 3.85% |
LoseNERV / S&P NERV unavailable / 0.20% |
LoseNERV / S&P NERV unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NERV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 117.37% | 20.78% |
| Annualized return | 117.37% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NERV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -63.97% | 83.14% |
| Annualized return | -18.47% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NERV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.81% | 319.30% |
| Annualized return | -25.61% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |